吕星

职务：中山大学肿瘤防治中心鼻咽科师生第二党支部书记，中山大学肿瘤防治中心人工智能实验室特聘临床专家，院职代会常设委员会委员。
职称：副主任医师
专长：鼻咽癌的个体化综合治疗及人工智能辅助诊断、治疗鼻咽癌

研究工作经历
2006～2011  中山大学       肿瘤学      硕博连读
2011～2012  住院医师       中山大学肿瘤防治中心
2012～2017  主治医师       中山大学肿瘤防治中心
2015~ 2021  科室秘书       中山大学肿瘤防治中心
2018～2022  副主任医师     中山大学肿瘤防治中心
2022/06至今，主任医师     中山大学肿瘤防治中心

学术兼职
中国医师协会放疗专业委员会 青年委员
中国抗癌协会肿瘤微环境专业委员会 青年委员
广东省抗癌协会放疗专业委员会青委会 副主任委员
广东省抗癌协会鼻咽癌专业委员会 青年委员
广东省医疗行业协会耳鼻喉头颈外科管理委员会 常委委员
广东省器官医学与技术学会肿瘤放疗专业委员会 副主任委员
广州市荔湾区医疗保健专家 顾问

科研课题
1.基于时序性磁共振图像的局部晚期鼻咽癌个体化化疗方案与实时预后预测的人工智能模型，国家自然科学基金面上项目，55万，执行年限：2022-2025，负责人。
2.基于人工智能和跨组学大数据的鼻咽癌诊治精准化研究，广东省自然科学基金杰出青年项目，100万，执行年限：2023-2026，负责人。
3.CD36促进鼻咽癌形成循环肿瘤细胞并启动鼻咽癌转移的分子机制及潜在治疗靶点的研究，广东省自然科学基金面上项目，10万 ，执行年限： 2021-2023，负责人。
4.基于光声成像的鼻咽癌激光免疫精准诊疗技术研究，广东省精准医学重大科技专项项目子课题，300万，执行年限：2019-2021，第二负责人。
5.Latexin调节肿瘤微环境促进鼻咽癌侵袭和转移分子机制的研究，广东省自然科学基金国际合作项目,50万，执行年限：2016-2017，负责人

发表论文
1.Lv X, Cao X, Xia WX, Liu KY, Qiang MY, Guo L, Qian CN, Cao KJ, Mo HY, Li XM, Li ZH, Han F, He YX, Liu YM, Wu SX, Bai YR, Ke LR, Qiu WZ, Liang H, Liu GY, Miao JJ, Li WZ, Lv SH, Chen X, Zhao C, Xiang YQ, Guo X. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):716-726. doi: 10.1016/S1470-2045(21)00075-9. Epub 2021 Apr 12. PMID: 33857411.
2.Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, Ye YF, Yang W, Zhang HX, Yuan TZ, Wang DS, Lu N, Ke LR, Tang WB, Tong LH, Chen ZJ, Liu T, Cao KJ, Mo HY, Guo L, Zhao C, Chen MY, Chen QY, Huang PY, Sun R, Qiu F, Luo DH, Wang L, Hua YJ, Tang LQ, Qian CN, Mai HQ, Guo X, Xiang YQ, Xia WX. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):706-714. doi: 10.1001/jamaoncol.2022.0122. PMID: 35323856; PMCID: PMC8949760.
3.Qiang M, Li C, Sun Y, Sun Y, Ke L, Xie C, Zhang T, Zou Y, Qiu W, Gao M, Li Y, Li X, Zhan Z, Liu K, Chen X, Liang C, Chen Q, Mai H, Xie G, Guo X, Lv X. A Prognostic Predictive System Based on Deep Learning for Locoregionally Advanced Nasopharyngeal Carcinoma. J Natl Cancer Inst. 2021 May 4;113(5):606-615. doi: 10.1093/jnci/djaa149. PMID: 32970812; PMCID: PMC8096375.
4.Li C, Jing B, Ke L, Li B, Xia W, He C, Qian C, Zhao C, Mai H, Chen M, Cao K, Mo H, Guo L, Chen Q, Tang L, Qiu W, Yu Y, Liang H, Huang X, Liu G, Li W, Wang L, Sun R, Zou X, Guo S, Huang P, Luo D, Qiu F, Wu Y, Hua Y, Liu K, Lv S, Miao J, Xiang Y, Sun Y, Guo X, Lv X. Development and validation of an endoscopic images-based deep learning model for detection with nasopharyngeal malignancies. Cancer Commun (Lond). 2018 Sep 25;38(1):59. doi: 10.1186/s40880-018-0325-9. PMID: 30253801; PMCID: PMC6156962.
5.Xia WX, Lv X, Liang H, Liu GY, Sun R, Zeng Q, Li SW, Mo HY, Han F, Luo DH, Liu Q, Shi MY, Ye YF, Yang J, Ke LR, Qiang MY, Qiu WZ, Yu YH, Liu KY, Huang XJ, Li WZ, Lv SH, Cai ZC, Miao JJ, Guo L, Chen MY, Cao KJ, Wang L, Zhao C, Huang PY, Chen QY, Hua YJ, Tang LQ, Qian CN, Mai HQ, Guo X, Xiang YQ. A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer. Clin Cancer Res. 2021 Aug 1;27(15):4186-4194. doi: 10.1158/1078-0432.CCR-20-4532. Epub 2021 Jun 3. PMID: 34083231; PMCID: PMC8974421.
6.Qiu WZ, Zhang HB, Xia WX, Ke LR, Yang J, Yu YH, Liang H, Huang XJ, Liu GY, Li WZ, Xiang YQ, Kang TB, Guo X, Lv X. The CXCL5/CXCR2 axis contributes to the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells by activating ERK/GSK-3β/snail signalling. J Exp Clin Cancer Res. 2018 Apr 17;37(1):85. doi: 10.1186/s13046-018-0722-6. PMID: 29665837; PMCID: PMC5905166.
7.Liu GY, Lv X, Wu YS, Mao MJ, Ye YF, Yu YH, Liang H, Yang J, Ke LR, Qiu WZ, Huang XJ, Li WZ, Guo X, Xiang YQ, Xia WX. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Cancer Commun (Lond). 2018 May 10;38(1):21. doi: 10.1186/s40880-018-0283-2. PMID: 29764487; PMCID: PMC5993041.
8.Liu K, Xia W, Qiang M, Chen X, Liu J, Guo X, Lv X. Deep learning pathological microscopic features in endemic nasopharyngeal cancer: Prognostic value and protentional role for individual induction chemotherapy. Cancer Med. 2020 Feb;9(4):1298-1306. doi: 10.1002/cam4.2802. Epub 2019 Dec 20. PMID: 31860791; PMCID: PMC7013063.
9.Cao X, Chen X, Lin ZC, Liang CX, Huang YY, Cai ZC, Li JP, Gao MY, Mai HQ, Li CF, Guo X, Lyu X. Add-on individualizing prediction of nasopharyngeal carcinoma using deep-learning based on MRI: A multicentre, validation study. iScience. 2022 Aug 3;25(9):104841. doi: 10.1016/j.isci.2022.104841. PMID: 36034225; PMCID: PMC9399485.
10.Chen X, Li Y, Li X, Cao X, Xiang Y, Xia W, Li J, Gao M, Sun Y, Liu K, Qiang M, Liang C, Miao J, Cai Z, Guo X, Li C, Xie G, Lv X. An interpretable machine learning prognostic system for locoregionally advanced nasopharyngeal carcinoma based on tumor burden features. Oral Oncol. 2021 Jul;118:105335. doi: 10.1016/j.oraloncology.2021.105335. Epub 2021 May 21. PMID: 34023742.
11.Chen X, Cao X, Jing B, Xia W, Ke L, Xiang Y, Liu K, Qiang M, Liang C, Li J, Gao M, Li W, Miao J, Liu G, Cai Z, Lv S, Guo X, Li C, Lv X. Prognostic and Treatment Guiding Significance of MRI-Based Tumor Burden Features and Nodal Necrosis in Nasopharyngeal Carcinoma. Front Oncol. 2020 Sep 11;10:537318. doi: 10.3389/fonc.2020.537318. PMID: 33042831; PMCID: PMC7518313.
12.Cai Z, Chen D, Qiu W, Liang C, Huang Y, Zhou J, Zhan Z, Xiang Y, Guo X, Lv X. Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis. J Cancer Res Clin Oncol. 2022 Oct 27. doi: 10.1007/s00432-022-04355-w. Epub ahead of print. PMID: 36289067.
13.Liu GY, Li WZ, Wang DS, Liang H, Lv X, Ye YF, Zhao C, Ke LR, Lv SH, Lu N, Bei WX, Cai ZC, Chen X, Liang CX, Guo X, Xia WX, Xiang YQ. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Apr 1;8(4):553-561. doi: 10.1001/jamaoncol.2021.7366. PMID: 35175316; PMCID: PMC8855317.
14.Liu YP, Lv X, Zou X, Hua YJ, You R, Yang Q, Xia L, Guo SY, Hu W, Zhang MX, Chen SY, Lin M, Xie YL, Liu LZ, Sun R, Huang PY, Fan W, Guo X, Hong MH, Chen MY. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma. Cancer Commun (Lond). 2019 Nov 15;39(1):75. doi: 10.1186/s40880-019-0415-3. PMID: 31730020; PMCID: PMC6858734.
15.Liang H, Xiang YQ, Lv X, Xie CQ, Cao SM, Wang L, Qian CN, Yang J, Ye YF, Gan F, Ke LR, Yu YH, Liu GY, Qiu WZ, Huang XJ, Wen CH, You N, Wang XQ, Guo X, Xia WX. Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: A large institution-based cohort study from an endemic area. Eur J Cancer. 2017 Mar;73:48-60. doi: 10.1016/j.ejca.2016.12.009. Epub 2017 Feb 3. PMID: 28161498.
16.Deng Y, Li C, Lv X, Xia W, Shen L, Jing B, Li B, Guo X, Sun Y, Xie C, Ke L. The contrast-enhanced MRI can be substituted by unenhanced MRI in identifying and automatically segmenting primary nasopharyngeal carcinoma with the aid of deep learning models: An exploratory study in large-scale population of endemic area. Comput Methods Programs Biomed. 2022 Apr;217:106702. doi: 10.1016/j.cmpb.2022.106702. Epub 2022 Feb 16. PMID: 35228147.
17.Liang H, Lv X, Wang L, Wu YS, Sun R, Ye YF, Ke LR, Yang Q, Yu YH, Qiu WZ, Liu GY, Huang XJ, Li WZ, Lv SH, Guo X, Xiang YQ, Xia WX. The plasma Epstein-Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area. Ther Adv Med Oncol. 2018 Jul 20;10:1758835918782331. doi: 10.1177/1758835918782331. PMID: 30046357; PMCID: PMC6055246.
18.Jing B, Deng Y, Zhang T, Hou D, Li B, Qiang M, Liu K, Ke L, Li T, Sun Y, Lv X, Li C. Deep learning for risk prediction in patients with nasopharyngeal carcinoma using multi-parametric MRIs. Comput Methods Programs Biomed. 2020 Dec;197:105684. doi: 10.1016/j.cmpb.2020.105684. Epub 2020 Aug 2. PMID: 32781421.
19.Xia WX, Liang H, Lv X, Wang L, Qian CN, Ye YF, Ke LR, Qiu WZ, Yu YH, Huang XJ, Liu GY, Zhao C, Xiang YQ, Guo X. Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis. Oral Oncol. 2017 Apr;67:167-174. doi: 10.1016/j.oraloncology.2017.02.026. Epub 2017 Mar 2. PMID: 28351572.
20.Ke LR, Xia WX, Qiu WZ, Huang XJ, Yu YH, Liang H, Liu GY, Xiang YQ, Guo X, Lv X. A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma. Oral Oncol. 2017 Jul;70:7-13. doi: 10.1016/j.oraloncology.2017.04.018. Epub 2017 May 9. PMID: 28622892.
21.Ke L, Deng Y, Xia W, Qiang M, Chen X, Liu K, Jing B, He C, Xie C, Guo X, Lv X, Li C. Development of a self-constrained 3D DenseNet model in automatic detection and segmentation of nasopharyngeal carcinoma using magnetic resonance images. Oral Oncol. 2020 Nov;110:104862. doi: 10.1016/j.oraloncology.2020.104862. Epub 2020 Jun 29. PMID: 32615440.
22.Liu K, Lin S, Ke L, Xia W, Zhang C, Li J, Gao M, Qiang M, Chen X, Liu J, Xie C, Guo X, Lv X. Prognostic value and the potential role of treatment options for cervical lymph node necrosis in nasopharyngeal carcinoma. Oral Oncol. 2020 Jun 27;109:104864. doi: 10.1016/j.oraloncology.2020.104864. Epub ahead of print. PMID: 32604061.
23.He C, Huang X, Su X, Tang T, Zhang X, Ma J, Guo X, Lv X. The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma. Cancer Biol Ther. 2017 Nov 2;18(11):888-894. doi: 10.1080/15384047.2017.1281493. Epub 2017 Jan 25. PMID: 28121221; PMCID: PMC5710676.
24.Ke LR, Xia WX, Qiu WZ, Huang XJ, Yang J, Yu YH, Liang H, Liu GY, Ye YF, Xiang YQ, Guo X, Lv X. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. BMC Cancer. 2017 Feb 15;17(1):134. doi: 10.1186/s12885-017-3080-4. PMID: 28202000; PMCID: PMC5311839.
25.Yu Y, Ke L, Xia WX, Xiang Y, Lv X, Bu J. Elevated Levels of TNF-α and Decreased Levels of CD68-Positive Macrophages in Primary Tumor Tissues Are Unfavorable for the Survival of Patients With Nasopharyngeal Carcinoma. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819874807. doi: 10.1177/1533033819874807. PMID: 31522611; PMCID: PMC6747870.
26.Qiu WZ, Ke LR, Xia WX, Yang J, Yu YH, Liang H, Huang XJ, Liu GY, Li WZ, Xiang YQ, Guo X, Lv X. A retrospective study of 606 cases of nasopharyngeal carcinoma with or without oropharyngeal candidiasis during radiotherapy. PLoS One. 2017 Aug 10;12(8):e0182963. doi: 10.1371/journal.pone.0182963. PMID: 28797119; PMCID: PMC5552301.

获奖情况
1.2018年中国临床肿瘤学会（CSCO）优秀论文二等奖
2.2020年度人民好医生金山茶花•杰出贡献奖 
3.中山大学肿瘤防治中心住院医师规范化培训优秀带教教师